수의학 안과 치료 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

Veterinary eye care market size in 2026 is estimated at USD 8.55 billion, growing from 2025 value of USD 8.28 billion with 2031 projections showing USD 10.07 billion, growing at 3.31% CAGR over 2026-2031.

Rising pet ownership, growing willingness to spend on premium treatments, and expanding portfolios of topical ophthalmic drugs position the veterinary eye care market for steady performance. Demand is buoyed by a higher incidence of ocular disorders such as keratoconjunctivitis sicca (KCS) and glaucoma, while breakthroughs in AI-enabled imaging and stem-cell therapies widen diagnostic and therapeutic reach. North America leads revenue contribution, yet Asia-Pacific delivers the fastest growth as pet humanization accelerates in urban economies. Competitive intensity remains moderate because no single company dominates every therapeutic class, though large players leverage integrated drug-device-data strategies to deepen engagement.

Global Veterinary Eye Care Market Trends and Insights

Growing Pet Ownership & Spend on Advanced Vet Care

Global pet humanization lifts treatment expectations and spending. Average ocular procedure outlays reach USD 1,100 for canine surgeries and USD 700-2,000 for feline eye treatments. Millennial and Gen Z owners in Asia-Pacific spur 10% yearly growth in regional pet health outlays, pushing the veterinary eye care market toward premium diagnostics and regenerative modalities. Tele-triage, wearable monitors, and AI screening tools integrate preventive workflows and encourage earlier referral, increasing service volumes. Hospitals respond by widening ophthalmic wings, and suppliers expand companion-animal drug lines to capture discretionary spend.

Rising Prevalence of Ocular Disorders (KCS, Ulcers, Glaucoma)

Breed genetics, longer pet lifespans, and environmental irritants lift disease caseloads. KCS now affects 1 in 22 dogs worldwide. Glaucoma contributes 8.47% of blindness presentations and often follows trauma or uveitis complications. Corneal ulcers respond better to anterior stromal puncture, which secures 80% healing, compared with 50% for standard debridement. The shortage of fewer than 600 board-certified veterinary ophthalmologists globally intensifies referral wait times. Higher disease visibility and unmet need translate into predictable revenue streams for drug manufacturers and surgical device suppliers.

High Cost of Advanced Ocular Equipment & Surgery

Phacoemulsification units, electroretinogram systems, and OCT scanners add investment burdens topping USD 100,000 per practice. Cataract removal runs USD 2,500-5,500 per eye in cats and USD 1,000-3,000 in dogs, limiting uptake among price-sensitive owners. Emerging-market clinics often refer complex cases to urban centers, concentrating procedure volumes and dampening regional diffusion.

Other drivers and restraints analyzed in the detailed report include:

1. Expanding Portfolio of Topical Ophthalmic Drugs & Ointments
2. AI-Enabled Imaging & Tele-Ophthalmology Adoption
3. Shortage of Board-Certified Veterinary Ophthalmologists

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Products delivered 76.83% of 2025 revenue, anchored by ophthalmic drugs, diagnostic devices, surgical instruments, and ocular implants. This dominance arises because every ophthalmic encounter-screening or surgery-relies on consumables and medications. AI-infused imaging devices and single-dose antibiotic-steroid drops extend product turnover cycles. The services arm, however, is the fastest climber at a 4.02% CAGR. Specialty surgeries, expanded diagnostic imaging, and virtual consultations lift average revenue per visit and soften the capital-equipment hurdle for clinics adopting subscription-based technology. Clinics package bundled postoperative checkups, further monetizing each procedure. As minimally invasive techniques propagate, disposable surgical packs and implantable lenses grow steadily, reinforcing cross-selling synergies across the veterinary eye care market.

Services momentum stems from widening cataract correction, which restores functional sight in up to 80% of treated animals over 30 months. Hospital networks respond with integrated perioperative care lines linked to AI imaging workflows, raising throughput without heavy manpower additions. Tele-ophthalmology platforms triage minor issues and route surgical candidates to regional centers, flattening geography-based capacity bottlenecks and prompting steady referrals into hospital pipelines.

Dogs captured 51.76% of 2025 revenue, consistent with their status as the most commonly owned companion animal in developed and emerging economies alike. Genetic predispositions, such as brachycephalic ocular syndrome and inherited cataracts, keep canine caseloads high, creating predictable drug volumes for KCS and glaucoma. The equine subsegment, although smaller in absolute terms, exhibits a 3.34% CAGR. Performance horse owners finance advanced surgeries and diagnostic imaging to preserve athletic value. Clinics tailor equine-specific anesthesia protocols and larger-format imaging accessories, opening bolt-on service revenues. Cats occupy a steady secondary niche with rising demand for tailored stem-cell therapies addressing eosinophilic keratitis.

Breed-targeted genetic testing kits expand preventive pathways and inform breeders' selections, directly influencing future ocular disease incidence. Allied specialty insurers design equine vision riders to offset high procedure costs, promoting early adoption of phacoemulsification and glaucoma valve implants in performance stables. Collectively, widening species-specific pipelines balance revenue diversity within the veterinary eye care market.

The Veterinary Eye Care Market Report is Segmented by Type (Eye Care Products and Eye Care Services), Indication (Ocular Surface Disorders, Glaucoma, Cataract, Infectious Diseases, and Other Indications), Application (Dog, Cat, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Geography Analysis

North America contributed 37.88% of 2025 revenue, underpinned by high pet healthcare outlay per animal and robust insurance penetration. The U.S. FDA Center for Veterinary Medicine oversees safety and efficacy reviews that take 2-4 years, aligning stakeholders on scientific rigor but lengthening launch cycles. Companies counterbalance by rolling AI upgrades and incremental device firmware to market within shorter notice periods, sustaining engagement until new molecules clear regulators. Academic clusters in California, Texas, and Ontario host renowned ophthalmology residencies, facilitating rapid dissemination of procedural innovations.

Asia-Pacific delivers the strongest growth at 3.92% CAGR on surging pet numbers, rising disposable income, and shifting demographics favoring single-person households over families. China's small-animal clinics have doubled within five years; Guangzhou alone fields about 400 veterinarians across 150 sites. Regional startups deploy mobile tele-consult kiosks inside pet retail outlets, lowering entry barriers for primary screening and funneling cases to urban hospitals. Government veterinary colleges in India and Thailand expand postgraduate ophthalmology seats, gradually easing specialist scarcity. The region's veterinary eye care market thus benefits from intersectional growth in both infrastructure and consumer readiness.

Europe comprises a mature secondary market with an entrenched referral culture linking general practices to ECVO diplomates. Residency programs across Germany, the Netherlands, and the United Kingdom collectively train new specialists but cannot fully offset retirements, keeping demand for tele-consults high. South America and Middle East & Africa represent emerging frontiers where cost hurdles and limited insurance stifle adoption, yet cross-border tele-ophthalmology fills access gaps. Multinational pharmaceutical companies pilot tiered-pricing strategies and donation programs to seed drug uptake, positioning for long-term volume gains as income levels rise.

1. Zoetis
2. Merck & Co., Inc. (MSD Animal Health)
3. Dechra Pharmaceuticals
4. Bausch + Lomb Corporation
5. Domes Pharma
6. I-Med Animal Health
7. Vetoquinol S.A.
8. Santicare LLC
9. Innovacyn
10. Ceva Sante Animale S.A.
11. Epicur Pharma
12. Neogen
13. Tarsus Pharmaceuticals Inc.
14. Topcon
15. Covetrus
16. Disop, S.A.
17. OCuSOFT Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing pet ownership & spend on advanced vet care
  • 4.2.2 Rising prevalence of ocular disorders (KCS, ulcers, glaucoma)
  • 4.2.3 Expanding portfolio of topical ophthalmic drugs & ointments
  • 4.2.4 Demand for minimally-invasive ophthalmic surgeries
  • 4.2.5 AI-enabled imaging & tele-ophthalmology adoption
  • 4.2.6 Stem-cell/regenerative therapies for corneal repair
• 4.3 Market Restraints
  • 4.3.1 High cost of advanced ocular equipment & surgery
  • 4.3.2 Limited insurance reimbursement for vet eye care
  • 4.3.3 Stringent regulatory approval timelines for vet drugs
  • 4.3.4 Shortage of board-certified veterinary ophthalmologists
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Products and Services
  • 5.1.1 Product
    • 5.1.1.1 Ophthalmic Drugs
    • 5.1.1.2 Surgical Instruments
    • 5.1.1.3 Diagnostic Devices & Imaging
    • 5.1.1.4 Ocular Implants & Disposables
  • 5.1.2 Services
    • 5.1.2.1 Ophthalmic Surgical Services
    • 5.1.2.2 Diagnostic Imaging Services
    • 5.1.2.3 Tele-Ophthalmology & Consultation
    • 5.1.2.4 Post-operative Care Services
• 5.2 By Animal Type
  • 5.2.1 Dogs
  • 5.2.2 Cats
  • 5.2.3 Horses
  • 5.2.4 Other Companion Animals
• 5.3 By Application
  • 5.3.1 Keratoconjunctivitis Sicca (Dry Eye)
  • 5.3.2 Conjunctivitis
  • 5.3.3 Corneal Ulcers & Injuries
  • 5.3.4 Glaucoma
  • 5.3.5 Uveitis & Retinal Disorders
  • 5.3.6 Others
• 5.4 By End-user
  • 5.4.1 Veterinary Hospitals
  • 5.4.2 Veterinary Clinics
  • 5.4.3 Academic & Research Institutes
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 South America
    • 5.5.4.1 Brazil
    • 5.5.4.2 Argentina
    • 5.5.4.3 Rest of South America
  • 5.5.5 Middle East and Africa
    • 5.5.5.1 GCC
    • 5.5.5.2 South Africa
    • 5.5.5.3 Rest of Middle East and Africa

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Zoetis Inc.
  • 6.3.2 Merck & Co., Inc. (MSD Animal Health)
  • 6.3.3 Dechra Pharmaceuticals PLC
  • 6.3.4 Bausch + Lomb Corporation
  • 6.3.5 Domes Pharma
  • 6.3.6 I-Med Animal Health
  • 6.3.7 Vetoquinol S.A.
  • 6.3.8 Santicare LLC
  • 6.3.9 Innovacyn Inc.
  • 6.3.10 Ceva Sante Animale S.A.
  • 6.3.11 Epicur Pharma
  • 6.3.12 Neogen Corporation
  • 6.3.13 Tarsus Pharmaceuticals Inc.
  • 6.3.14 Topcon Corporation
  • 6.3.15 Covetrus, Inc.
  • 6.3.16 Disop, S.A.
  • 6.3.17 OCuSOFT Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment